Monday, June 22, 2015
AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company’s global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.
AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin’s lymphoma, myelodysplastic syndromes and multiple myeloma.
MedImmune, the global biologics R&D arm of AstraZeneca, and Joslin Diabetes Center, a diabetes research and clinical care organization based in Boston, Mass., have inked a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity and related metabolic disorders.
MedImmune, the global biologics R&D arm of AstraZeneca, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed a five-year agreement to jointly support research that will help advance drug discovery and manufacturing. The effort will focus on tools and measurements that will be used in the development and production of biopharmaceuticals, which are drugs and treatments derived from biological, rather than chemical, sources.
Inovio Pharmaceuticals has appointed Mark Stephen Gelder, M.D., as vice president, clinical development. Gelder will be responsible for planning and executing Inovio’s clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio’s chief medical officer.
Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune’s antibody drug discovery programs.